Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Supportive and palliative care 1

2062 - Factors that influence oncology nutrition efficacy in breast cancer patients under antiestrogenic treatment


20 Oct 2018


Poster Discussion session - Supportive and palliative care 1


Supportive Care and Symptom Management

Tumour Site

Breast Cancer


Diana Artene


Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300


D.V. Artene1, A. Blidaru2

Author affiliations

  • 1 Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 - Bucharest/RO
  • 2 Surgical oncology, Alexandru Trestioreanu Oncology Institute, 022328 - Bucharest/RO


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2062


Many breast cancer patients gain weight during treatment increasing recurrence, metastasis and mortality risks. The diagnosis overthrows patients’ lifestyle aggravating sedentariness and any pre-existing weight gain causes like insulin and leptin resistance, sleep disturbances and hedonic eating.


To test the efficacy of an at-home oncology nutrition intervention meant to stop weight gain during antiestrogenic treatment we proposed a diet based on foods naturally high in proteins, omega-3 fatty acids, calcium, probiotics and prebiotics. 331 patients were randomly assigned to the control group, with no oncology nutrition advice besides the physician recommendation to avoid weight gain. 283 patients were randomly assigned to the intervention group and asked to follow the proposed diet. We measured weight and body composition and we compared results at 24 months between intervention and control groups. Then we analysed the results based on the administered oncology treatment type and patients’ age, comorbidities, lifestyle characteristics.


At 24 months, patients within the intervention group reached a modest but statistically significant weight loss and fat loss with no sarcopenia (2.44kg weight loss, 2.37% subcutaneous fat loss, 0.65% visceral fat loss, 1,24% muscle mass increase), while those in the control group maintained weight, increased fat and lost muscle (0.35kg weight loss, 0.34% subcutaneous fat increase, 0.4% visceral fat increase, 0.42 muscle mass decrease). Efficacy was influenced by: age – 31-40 yo patients having worse results than 41-50 yo patients and than 51-80 yo patients; AET type – patients on letrozole having best results; de novo thyroidal disease – lowered fat loss; depression – lowered fat loss; statins – when co-administrated throughout exemestane treatment – lowered fat loss; sleep disturbances – increased sarcopenia. Efficacy was not influenced by: chemotherapy or radiotherapy administration, type of surgery, cardiovascular disease, smoking or by the dieting history.


Oncology nutrition interventions can counteract sarcopenic obesity during antiestrogenic treatment, but the efficacy of the intervention can be influenced by patients’ age and comorbidities.

Clinical trial identification

Legal entity responsible for the study

Carol Davila Medicine University.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.